ARS Pharmaceuticals, Inc.

Spooky season can be even spookier for parents of children with food allergies. Thanks to FARE’s Teal Pumpkin Project, everyone (food allergy family or not!) can bring the magic back to Halloween this year. ✨ Here’s how: 🪀 Purchase non-food treats for Halloween 📍 Add your address to the Teal Pumpkin Project Map 🪧 Show your support by hanging a free printable sign 😊 On Halloween, enjoy sharing non-food treats with trick-or-treaters who have a food allergy Click here for resources from FARE including ideas for non-food treats and printable signage: https://bit.ly/4faxwNT #foodallergy #halloween #tealpumpkinproject #foodallergies #community

#NEWS: ARS Pharmaceuticals will showcase our comprehensive clinical research of Type 1 allergy treatment, including anaphylaxis, with seven poster presentations at 2024 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting. The posters will highlight a wide range of studies focused on intranasal administration, including cardiovascular safety, human factor study of carrying two devices at all times, and real-world administration data in pediatric patients. Learn more and get the times here: https://bit.ly/4fihP7q #ACAAImeeting #Innovation #Science #ARSPharma 

The FDA approved our needle-free treatment option for patients and families living with severe allergic reactions in August and our team worked fast to make it available as quickly as possible. Read more about how to get a prescription, insurance support and more in this Allergic Living article featuring our CEO Richard Lowenthal: https://bit.ly/3N2VqPw     To learn more about our treatment option click here: https://bit.ly/3Xu51ER    #biotechnews #biotech #science #allergy 

ARS Pharmaceuticals is honored to be part of the We are FARE Food Allergy Summit hosted by FARE. There are two different opportunities to connect with us and learn more about our recent innovation in treating Type 1 allergies, including anaphylaxis. We hope to see you there and look forward to an inspirational few days. #WeAreFARE #FoodAllergy #FARESummit #ARSPharma

We are looking forward to this week’s We Are FARE Food Allergy Summit in Washington D.C. The annual event hosted by FARE brings together people impacted by #foodallergies and those who support them for educational sessions, important discussions and impactful connections. We are grateful for the work FARE does and for this meaningful event. Learn more: https://bit.ly/4eSMM1U #WeAreFARE #FoodAllergy #FARESummit #ARSPharma

#News about our recent #FDAapproval was featured on the Nasdaq Tower in #TimesSquare. To learn more about our treatment option, click here: https://bit.ly/3Xu51ER #biotechnews #biotech #science

People who live with a #foodallergy do not choose to avoid certain foods because of preference, it’s to prevent a range of symptoms that can be life-threatening. It’s important to continue to spread education about food allergy and support those who navigate food allergies daily.   

EMS personnel in Avery County, North Carolina put out a call for emergency medication for people who have Type 1 severe allergies, including anaphylaxis. An increase in insect bites, particularly from yellow jackets, have led to a spike in anaphylactic reactions in the region. Please share with local residents and volunteers that we’ve donated our FDA approved treatment to the United Way to help with increased demand due to Hurricane Helene. If anyone is in need of treatment for their Type 1 severe allergic reaction, encourage them to visit Chesapeake Regional Healthcare Mobile Clinic.

We're #hiring a new Payroll Manager in San Diego, California. Apply today or share this post with your network.

Allergic reactions result in an estimated 500,000 emergency room visits each year, with nearly 60% of such patients reported to not have received #epinephrine prior to visiting the emergency room. That’s why our team developed a new treatment option for patients and families living with severe allergic reactions. #ARSPharma #Innovation